• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atai Life Sciences N.V. (NQ: ATAI )

    1.080 +0.020 (+1.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Atai Life Sciences N.V.

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    26 27 Next >
    atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
    From atai Life Sciences
    Via GlobeNewswire
    Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
    Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
    Via Benzinga
    Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
    Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
    Via Benzinga
    Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
    The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
    Via Talk Markets
    MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
    Via Benzinga
    Exposures Product Safety
    Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
    While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
    Via Talk Markets
    Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
    The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
    Via Talk Markets
    Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
    The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
    Via Talk Markets
    Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
    Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targeting treatment-resistant patients. 
    Via Benzinga
    ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
    ATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From atai Life Sciences
    Via GlobeNewswire
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
    Via Benzinga
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    3 Dirt-Cheap Drug Developers With Blockbuster Potential
    These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
    Via InvestorPlace
    3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
    These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases. 
    Via InvestorPlace
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
    Via InvestorPlace
    Exposures Product Safety
    Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
    Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
    Via InvestorPlace
    3 Psychedelic Stocks to Buy on the Dip: Summer 2024
    These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
    Via Talk Markets
    atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
    From atai Life Sciences
    Via GlobeNewswire
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
    Via Talk Markets
    Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
    FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
    Via Benzinga
    Exposures Product Safety
    What's Going On With MindMed And Psychedelic Stocks?
    Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    26 27 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.